Vol 2, No 1 (February 14, 2013): Translational Lung Cancer Research

Incomplete intrapulmonary lymph node retrieval after routine pathologic examination of resected lung cancer

New insights into the functional consequences of ephrin A3 mutations in non-small cell lung cancer

Is overall survival still the primary endpoint in maintenance non-small cell lung cancer studies? An analysis of phase III randomised trials

Inhibition of insulin-like growth factor receptor: end of a targeted therapy?

MET inhibition in lung cancer

Irreversible EGFR-TKIs: dreaming perfection

Does the order of factors affect the product? Lessons learned from the TORCH trial

Keeping our fingers crossed on 2^nd generation EGFR TKIs: is better good enough?

Front-line erlotinib in unselected patients with advanced NSCLC and poor performance status - the TOPICAL study

The TOPICAL study should be more topical!

ZEPHYR illustrates the perils of testing targeted treatments in unselected non-small-cell lung cancer patients

ZEPHYR: failure of a “spring wind” in lung cancer

Vandetanib in advanced non small cell lung cancer: a promise unfulfilled

Antiangiogenic tyrosine kinase inhibitors in non-small-cell-lung cancer: lights and shadows

Angiogenesis, multitarget kinase inhibitors and non-small cell lung cancer: a lesson from MONET1 trial

Targeted versus chrono-targeted chemotherapy for inhaled chemotherapy in non-small cell lung cancer

Dr Haiquan Chen: clinical significance of RET fusion gene for patients with NSCLC

Recurrent left chest mass: a case report

Endobronchial carcinoid tumor in a Crohn disease patient treated with a TNFα inhibitor